April 12, 2017
FDA OKs Neurocrine Biosciences’s neurological disorder drug
The U.S. Food and Drug Administration has approved Neurocrine Biosciences’s Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: tardive dyskinesia